Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 698

2.

Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds.

Ravinder, Bhaskar, Gangwar S, Goyal N.

Curr Microbiol. 2012 Dec;65(6):696-700. doi: 10.1007/s00284-012-0209-1. Epub 2012 Sep 4.

PMID:
22945482
3.

High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.

Aulner N, Danckaert A, Rouault-Hardoin E, Desrivot J, Helynck O, Commere PH, Munier-Lehmann H, Späth GF, Shorte SL, Milon G, Prina E.

PLoS Negl Trop Dis. 2013 Apr 4;7(4):e2154. doi: 10.1371/journal.pntd.0002154. Print 2013.

4.

Effect of allicin on promastigotes and intracellular amastigotes of Leishmania donovani and L. infantum.

Jesús Corral-Caridad M, Moreno I, Toraño A, Domínguez M, Alunda JM.

Exp Parasitol. 2012 Dec;132(4):475-82. doi: 10.1016/j.exppara.2012.08.016. Epub 2012 Sep 17.

PMID:
22995646
5.

Visceral leishmaniasis: experimental models for drug discovery.

Gupta S; Nishi.

Indian J Med Res. 2011 Jan;133:27-39. Review.

6.

Leishmania donovani: assessment of leishmanicidal effects of herbal extracts obtained from plants in the visceral leishmaniasis endemic area of Bihar, India.

Singh SK, Bimal S, Narayan S, Jee C, Bimal D, Das P, Bimal R.

Exp Parasitol. 2011 Feb;127(2):552-8. doi: 10.1016/j.exppara.2010.10.014. Epub 2010 Nov 9.

PMID:
21070771
7.

Rapid fluorescent assay for screening drugs on Leishmania amastigotes.

Shimony O, Jaffe CL.

J Microbiol Methods. 2008 Oct;75(2):196-200. doi: 10.1016/j.mimet.2008.05.026. Epub 2008 Jun 5.

PMID:
18573286
8.

Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes.

Paape D, Bell AS, Heal WP, Hutton JA, Leatherbarrow RJ, Tate EW, Smith DF.

PLoS Negl Trop Dis. 2014 Dec 18;8(12):e3363. doi: 10.1371/journal.pntd.0003363. eCollection 2014 Dec.

9.

Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Osorio Y, Travi BL, Renslo AR, Peniche AG, Melby PC.

PLoS Negl Trop Dis. 2011 Feb 15;5(2):e962. doi: 10.1371/journal.pntd.0000962.

10.

Use of in vitro method to assess different brands of anti-leishmanial drugs.

Arora SK, Sinha R, Sehgal S.

Med Microbiol Immunol. 1991;180(1):21-7.

PMID:
2056963
11.

An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1.

Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D.

Acta Trop. 1992 Aug;51(3-4):237-45.

PMID:
1359751
12.

Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening.

Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A.

J Antimicrob Chemother. 2009 Aug;64(2):370-4. doi: 10.1093/jac/dkp206. Epub 2009 Jun 12.

13.

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, Maes L.

Antimicrob Agents Chemother. 2009 Sep;53(9):3855-9. doi: 10.1128/AAC.00548-09. Epub 2009 Jun 22.

14.

Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.

Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D.

Antimicrob Agents Chemother. 1999 Feb;43(2):278-82.

15.

Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.

De Rycker M, Hallyburton I, Thomas J, Campbell L, Wyllie S, Joshi D, Cameron S, Gilbert IH, Wyatt PG, Frearson JA, Fairlamb AH, Gray DW.

Antimicrob Agents Chemother. 2013 Jul;57(7):2913-22. doi: 10.1128/AAC.02398-12. Epub 2013 Apr 9. Erratum in: Antimicrob Agents Chemother. 2014 Dec;58(12):7622.

16.

In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in Leishmania donovani infection.

Dayakar A, Chandrasekaran S, Veronica J, Sundar S, Maurya R.

Exp Parasitol. 2015 Jun;153:45-54. doi: 10.1016/j.exppara.2015.02.011. Epub 2015 Mar 3.

PMID:
25747203
17.

High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay.

Mandal S, Maharjan M, Ganguly S, Chatterjee M, Singh S, Buckner FS, Madhubala R.

Indian J Exp Biol. 2009 Jun;47(6):475-9.

18.

Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents.

Taylor VM, Muñoz DL, Cedeño DL, Vélez ID, Jones MA, Robledo SM.

Exp Parasitol. 2010 Dec;126(4):471-5. doi: 10.1016/j.exppara.2010.05.016. Epub 2010 May 26.

PMID:
20685203
19.

Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis.

Chakrabarti G, Basu A, Manna PP, Mahato SB, Mandal NB, Bandyopadhyay S.

J Antimicrob Chemother. 1999 Mar;43(3):359-66.

20.

An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages.

Siqueira-Neto JL, Moon S, Jang J, Yang G, Lee C, Moon HK, Chatelain E, Genovesio A, Cechetto J, Freitas-Junior LH.

PLoS Negl Trop Dis. 2012;6(6):e1671. doi: 10.1371/journal.pntd.0001671. Epub 2012 Jun 12.

Items per page

Supplemental Content

Write to the Help Desk